These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 35270708)

  • 1. Antiviral Drugs in Influenza.
    Świerczyńska M; Mirowska-Guzel DM; Pindelska E
    Int J Environ Res Public Health; 2022 Mar; 19(5):. PubMed ID: 35270708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
    Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
    Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients].
    Taieb V; Ikeoka H; Ma F; Borkowska K; Aballea S; Tone K; Hirotsu N
    Ter Arkh; 2020 Dec; 92(11):122-131. PubMed ID: 33720617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
    Komeda T; Takazono T; Hosogaya N; Ogura E; Fujiwara M; Miyauchi H; Ajisawa Y; Iwata S; Watanabe H; Honda K; Kitanishi Y; Hara K; Mukae H
    Clin Infect Dis; 2021 Jun; 72(11):e859-e867. PubMed ID: 33103200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the incidence of bleeding between baloxavir marboxil and other anti-influenza drugs among outpatients with influenza virus infection: A retrospective cohort study using an employment-based health insurance claims database in Japan.
    Hara A; Hara K; Komeda T; Ogura E; Miyazawa S; Kobayashi C; Fujiwara M; Yoshida M; Urushihara H
    Pharmacoepidemiol Drug Saf; 2022 Jun; 31(6):623-631. PubMed ID: 34881477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
    Komeda T; Takazono T; Hosogaya N; Miyazaki T; Ogura E; Iwata S; Miyauchi H; Honda K; Fujiwara M; Ajisawa Y; Watanabe H; Kitanishi Y; Hara K; Mukae H
    Clin Infect Dis; 2021 Sep; 73(5):e1181-e1190. PubMed ID: 33354728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients.
    Taieb V; Ikeoka H; Ma FF; Borkowska K; Aballéa S; Tone K; Hirotsu N
    Curr Med Res Opin; 2019 Aug; 35(8):1355-1364. PubMed ID: 30810054
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiviral Treatments for Influenza.
    Palomba E; Castelli V; Renisi G; Bandera A; Lombardi A; Gori A
    Semin Respir Crit Care Med; 2021 Dec; 42(6):859-872. PubMed ID: 34918326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis.
    Taieb V; Ikeoka H; Wojciechowski P; Jablonska K; Aballea S; Hill M; Hirotsu N
    Curr Med Res Opin; 2021 Feb; 37(2):225-244. PubMed ID: 33079575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.
    Kumar D; Ison MG; Mira JP; Welte T; Hwan Ha J; Hui DS; Zhong N; Saito T; Katugampola L; Collinson N; Williams S; Wildum S; Ackrill A; Clinch B; Lee N
    Lancet Infect Dis; 2022 May; 22(5):718-730. PubMed ID: 35085510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid health technology assessment of the novel endonuclease inhibitor baloxavir for the treatment of influenza.
    Huang G; Tian Y; Cui W; Zhang X; Zhao Y; Liu X
    J Chemother; 2024 Jul; 36(4):267-282. PubMed ID: 37767970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report.
    Harada N; Shibata W; Koh H; Takashita E; Fujisaki S; Okamura H; Nanno S; Yamada K; Nakamae H; Hino M; Kakeya H
    BMC Infect Dis; 2020 Jul; 20(1):478. PubMed ID: 32631240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis.
    Liu JW; Lin SH; Wang LC; Chiu HY; Lee JA
    JAMA Netw Open; 2021 Aug; 4(8):e2119151. PubMed ID: 34387680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral influenza treatments and hemorrhage-related adverse events in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database.
    Sarker J; Carkovic E; Ptaszek K; Lee TA
    Pharmacotherapy; 2024 May; 44(5):383-393. PubMed ID: 38656741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuraminidase inhibitors for preventing and treating influenza in children.
    Wang K; Shun-Shin M; Gill P; Perera R; Harnden A
    Cochrane Database Syst Rev; 2012 Jan; 1():CD002744. PubMed ID: 22258949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials.
    Tejada S; Tejo AM; Peña-López Y; Forero CG; Corbella X; Rello J
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):901-918. PubMed ID: 33861168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza.
    Abraham GM; Morton JB; Saravolatz LD
    Clin Infect Dis; 2020 Oct; 71(7):1790-1794. PubMed ID: 32020174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spread of viral infection to family members from influenza patients treated with a neuraminidase inhibitor.
    Nakano T; Shiosakai K
    J Infect Chemother; 2014 Jul; 20(7):401-6. PubMed ID: 24787736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.